Equity Research Initiated on Advaxis by Zacks Equity Research

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) vaccine company, has been given an investment rating by Zack's Equity Research, an investment research company, in their research evaluation of the Company.

Zacks’ 18-page report includes detailed information about Advaxis' proprietary platform technology, the healthcare/immunotherapy market, industry peer comparisons and Advaxis’ growth strategies along with their recommendations. For a free copy of the full research report, please email Zack's Equity Research [email protected] with “ADXS” as the subject.

Company Notice on Zack's Equity Research

Any opinions, judgments, estimates, or forecasts regarding Advaxis' historical or predicted performance or operations made by Zacks are its alone and do not represent opinions, judgments, estimates, or forecasts of Advaxis or its management. Advaxis does not by its reference to the research prepared by Zacks imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live but attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Our platform technology was developed by Dr. Yvonne Paterson at The University of Pennsylvania. Today, the Company has over nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research – UK, the University of British Columbia and the Department of Homeland Security. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis Incorporated
Conrad F. Mir
Executive Director
609-952-9813 (Office)
609-952-9818 (FAX)
[email protected]
or
Advaxis Incorporated
Diana Moore
Analyst
609-952-9813 (Office)
609-952-9818 (FAX)
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Pharmaceutical  Other Health  Professional Services  Banking  Finance

MEDIA:

Logo
 Logo

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.